본문 바로가기
KERD
논문KCI 등재

Effect of the Dysbindin Gene on Antimanic Agents in Patients with Bipolar I Disorder

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

주제분류정신과학

초록

Objective: We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment. Methods: A total of 45 BID patients were treated with antimanic agents (lithium, valproate, or carbamazepine) for an average of 36.52 (±19.87) days. After treatment, the patients were evaluated using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS) and genotyped for their DTNBP1 variants (rs3213207 A/G, rs1011313 C/T, rs2005976 G/A, rs760761 C/T and rs2619522 A/C). Results: There was no association between the variants investigated and response to mood stabilizer treatment, even after considering possible stratification factors. Conclusion: Although the small number of subjects is an important limitation in our study, DTNBP1 does not seem to be involved in acute antimanic efficacy.

Abstract

Objective: We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment. Methods: A total of 45 BID patients were treated with antimanic agents (lithium, valproate, or carbamazepine) for an average of 36.52 (±19.87) days. After treatment, the patients were evaluated using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS) and genotyped for their DTNBP1 variants (rs3213207 A/G, rs1011313 C/T, rs2005976 G/A, rs760761 C/T and rs2619522 A/C). Results: There was no association between the variants investigated and response to mood stabilizer treatment, even after considering possible stratification factors. Conclusion: Although the small number of subjects is an important limitation in our study, DTNBP1 does not seem to be involved in acute antimanic efficacy.

참고문헌 (27)

  1. Althoff RR, "Family, twin, adoption, and molecular genetic studies of juvenile bipolar disorder", Bipolar Disord, 7, pp.598~609 (2005)
  2. Savitz JB, "Trends in suicidology: personality as an endophenotype for molecular genetic investigations", PLoS Med, 3, pp.e107~ (2006)
  3. Malhotra AK, "Pharmacogenetics of psychotropic drug response", Am J Psychiatry, 161, pp.780~796 (2004)
  4. Savitz J, "Neuropsychological dysfunction in bipolar affective disorder: a critical opinion", Bipolar Disord, 7, pp.216~235 (2005)
  5. Zhou R, "Identification of molecular mechanisms underlying mood stabilization through genome-wide gene expression profiling", Int J Neuropsychopharmacol, 9, pp.263~266 (2006)
  6. Benson MA, "Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain", J Biol Chem, 276, pp.24232~24241 (2001)
  7. Iizuka Y, "Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization", J Neurosci, 27, pp.12390~12395 (2007)
  8. Amerian Psychiatric Association, "Practice guideline for the treatment of patients with bipolar disorder", Am J Psychiatry, 151, pp.1~36 (1994)
  9. Kleindienst N, "Psychosocial and demographic factors associated with response to prophylactic lithium: a systematic review for bipolar disorders", Psychol Med, 35, pp.1685~1694 (2005)
  10. Ruzickova M, "Pharmacogenetics and mood stabilization in bipolar disorder", Am J Med Genet C Semin Med Genet, 123C, pp.18~25 (2003)
  11. Rowe MK, "Lithium neuroprotection: molecular mechanisms and clinical implications", Expert Rev Mol Med, 6, pp.1~18 (2004)
  12. Alda M, "Investigating responders to lithium prophylaxis as a strategy for mapping susceptibility genes for bipolar disorder", Prog Neuropsychopharmacol Biol Psychiatry, 29, pp.1038~1045 (2005)
  13. Rao JS, "Chronic NMDA administration to rats up-regulates frontal cortex cytosolic phospholipase A2 and its transcription factor, activator protein-2", J Neurochem, 102, pp.1918~1927 (2007)
  14. Kazuno AA, "Relationships between mitochondrial DNA subhaplogroups and intracellular calcium dynamics", Mitochondrion, 8, pp.164~169 (2008)
  15. Einat H, "Modelling facets of mania--new directions related to the notion of endophenotypes", J Psychopharmacol, 20, pp.714~722 (2006)
  16. Kishimoto M, "The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis", Biol Psychiatry, 63, pp.191~196 (2008)
  17. Duan J, "DTNBP1 (Dystrobrevin binding protein 1) and schizophrenia: association evidence in the 3’ end of the gene", Hum Hered, 64, pp.97~106 (2007)
  18. Pae CU, "Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy", Pharmacogenet Genomics, 17, pp.69~75 (2007)
  19. Schwab SG, "Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families", Am J Hum Genet, 72, pp.185~190 (2003)
  20. American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)" (1994), American Psychiatric Association
  21. Yildiz-Yesiloglu A, "Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings", Prog Neuropsychopharmacol Biol Psychiatry, 30, pp.969~995 (2006)
  22. Kugaya A, "Sanacora G. Beyond monoamines: glutamatergic function in mood disorders", CNS Spectr, 10, pp.808~819 (2005)
  23. Abelli M, "The role of newer antiglutamatergic agents as mood-stabilizers in bipolar disorder", Curr Drug Targets, 6, pp.607~614 (2005)
  24. Goodnick PJ, "Anticonvulsants in the treatment of bipolar mania", Expert Opin Pharmacother, 7, pp.401~410 (2006)
  25. Pae CU, "Effect of 5-haplotype of dysbindin gene (DTNBP1) polymorphisms for the susceptibility to bipolar I disorder", Am J Med Genet B Neuropsychiatr Genet, 144B, pp.701~703 (2007)
  26. Raybould R, "Bipolar disorder and polymorphisms in the dysbindin gene (DTNBP1)", Biol Psychiatry, 57, pp.695~701 (2005)
  27. Zill P, "The dysbindin gene in major depression: an association study", Am J Med Genet B Neuropsychiatr Genet, 129B, pp.55~58 (2004)

관련 논문AI추천

Association of the Brain-derived Neurotrophic Factor Gene and Clinical Features of Bipolar Disorder in Korea이은, 김세주, 석정호, 전덕인, 조현상, Hye Ji Min대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2012 · 제10권 제3호Neuromolecular Etiology of Bipolar Disorder: Possible Therapeutic Targets of Mood Stabilizers박성우, 박원명, 이정구, Dae-Hyun Seog, Mi Kyoung Seo, Young Sup Woo대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2022 · 제20권 제2호Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor in Bipolar Mania: An Exploratory StudyBiswa Ranjan Mishra, Debadatta Mohapatra, Debasis Bisoi, Jaseem Jowhar, Rituparna Maiti, Sansita Parida대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2017 · 제15권 제2호Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder배치운, 이수정, 한창수, Alessandro Serretti, Ashwin A Patkar, Beatrice Balzarro, Diana De Ronchi, Prakash S. Masand, Siegfried Alberti, Stefano Porcelli대한신경정신의학회 · PSYCHIATRY INVESTIGATION2014 · 제11권 제4호Association of CACNA1C Variants with Bipolar Disorder in the Korean Population조철현, Dongho Geum, Heon-Jeong Lee, Soojin Kim대한신경정신의학회 · PSYCHIATRY INVESTIGATION2016 · 제13권 제4호Relationship between Polygenic Risk Score and the Hypnotics in Bipolar I DisorderBun-Hee Lee, Hyeon Woo Lee, John R. Kelsoe, Tatyana Shekhtman, Young-Min Park대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2024 · 제22권 제4호

이 간행물의 다른 논문 (5건)